Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Getinge ABCHIX:GETIBS 73 EBIT per Share is kr16.46 as of Jun. 2026. GuruFocus rates CHIX:GETIBS with a GF Score™ of 73/100 and a GF Value™ of kr192.70 (Modestly Overvalued). The stock has 10 warning signs investors should review. Among 684 Medical Devices & Instruments companies, Getinge AB ranks worse than 56.87% on this metric.
Getinge AB's EBIT per Share for the
three
months ended in Jun. 2026 was kr4.96.
Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 was kr16.46.
During the past 12 months, the average EBIT per Share Growth Rate of Getinge AB was 16.90% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 4.80% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -3.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Getinge AB's EBIT per Share or its related term are showing as below:
CHIX:GETIBs'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -24.9 Med: 2.5 Max: 66.4
Current: 4.8
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Getinge AB was 66.40% per year. The lowest was -24.90% per year. And the median was 2.50% per year.
CHIX:GETIBs's 3-Year EBIT Growth Rate is ranked worse than 56.87% of 684
companies
in the Medical Devices & Instruments industry
Industry Median: 9.6
vs CHIX:GETIBs: 4.80
Getinge AB's EBIT for the
three
months ended in Jun. 2026 was kr1,351 Mil.
Getinge AB (CHIX:GETIBs) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Getinge AB EBIT per Share Related Terms
Getinge AB EBIT per Share Historical Data
* Premium members only.
The historical data trend for Getinge AB's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr16.46
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Getinge AB (CHIX:GETIBS) has a EBIT per Share of kr16.46 as of Jun. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Getinge AB and its competitors. According to the industry distribution chart, Getinge AB ranks #389 out of 684 companies in the Medical Devices & Instruments industry, placing it in the top 56.9%.
Is Getinge AB's EBIT per Share too high?
Getinge AB's current EBIT per Share is kr16.46. Based on the distribution chart, Getinge AB ranks #389 out of 684 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Getinge AB has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Getinge AB's EBIT per Share compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Getinge AB ranks #389 out of 684 companies for EBIT per Share. This places Getinge AB in the lower half of its industry. The industry median EBIT per Share is 9.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.60, based on 684 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Getinge AB and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Getinge AB's current EBIT per Share is kr16.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Getinge AB stock overvalued right now?
Based on GuruFocus' analysis, Getinge AB (CHIX:GETIBS) is currently considered Modestly Overvalued. The stock's GF Value™ is kr192.70, compared to a current price of kr231.00 — trading 19.9% above its estimated fair value. The current EBIT per Share is kr16.46. Getinge AB's overall GF Score™ is 73/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Getinge AB (CHIX:GETIBS), the current EBIT per Share is kr16.46 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Getinge AB (CHIX:GETIBS) Overvalued in 2026?
Based on GuruFocus' analysis, Getinge AB stock appears to be overvalued.
The current stock price of kr231.00 is trading 19.9% above its estimated GF Value™ of kr192.70.
GuruFocus considers Getinge AB to be Modestly Overvalued.
Key valuation signals for CHIX:GETIBS:
EBIT per Share: kr16.46
GF Value™: kr192.70 vs. price of kr231.00 (19.9% above fair value)
No single metric tells the full story. See the CHIX:GETIBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Getinge, headquartered in Gothenburg, Sweden, manufactures a wide range of products for use in acute care, surgical, and life sciences in the hospital, pharmaceutical, and research settings. The company reports in three segments: acute care therapies (52% of revenue), surgical workflows (35%), and life sciences (13%). Product areas include ventilators, surgical stents, life support systems, sterilizers, surgical tables, and sterile transfer systems. Getinge derives revenue from a broad geographic footprint, with the Americas accounting for 45% of sales, Europe, Middle East, and Africa 35%, and Asia-Pacific the remaining 25%.
73GF Score
Get the complete analysis for CHIX:GETIBS
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:GETIBS has been successfully added to your 
